In addition, Dennis (2018) found that RICTOR mutations were present in early and advanced lung adenocarcinomas, and the amplification of RICTOR predicted poor overall survival in advanced LUAD patients (OS, HR: 1.73, 95% CI: 1.23–2.42, p = 0.0015). Here, RICTOR is linked to lung adenocarcinoma.